Business Wire: Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive ...
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive ...
Morningstar: Ferring Announces Update to NCCN Guidelines Expanding Category 2A Recommendation for Nadofaragene Firadenovec-vncg (ADSTILADRIN®) in Patients with BCG-Unresponsive NMIBC
Ferring Announces Update to NCCN Guidelines Expanding Category 2A Recommendation for Nadofaragene Firadenovec-vncg (ADSTILADRIN®) in Patients with BCG-Unresponsive NMIBC
Researchers gave the patients verbal commands and measured patients’ mental activity through brain wave tests and functional MRIs. When a patient with a brain injury is unresponsive, doctors turn to ...
Morningstar: ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease Recommendation ...
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...
Nasdaq: ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 ...
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 ...
MedPage Today: How TAR-200 Therapy Fared in Patients With BCG-Unresponsive High-Risk NMIBC
A recent phase IIb SunRISe-1 study by Daneshmand, et al. evaluated TAR-200 therapy alone or in combination with cetrelimab in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk ...
Business Wire: ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N ...
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N ...
NBC News: Brain scans of some unresponsive hospital patients show detectable activity
When a patient with a brain injury is unresponsive, doctors turn to certain basic tests to see if they could still have some awareness: calling their name, clapping near their ear or inserting a ...
At least 25% of unresponsive patients with a disorder of consciousness show signs of brain activity, an estimate that is higher than previous studies suggest. "We found that at least 1 in 4 patients ...
Yahoo Finance: ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...
New research co-led by experts at Mass General Brigham found that brain scans can detect consciousness in some patients with brain injury who are unresponsive. In the study, 241 participants with ...